Le Lézard
Classified in: Covid-19 virus
Subjects: GOVERNMENT CONTRACTS, MISCELLANEOUS

Bruske welcomes NDP commitment to end profiteering off of seniors' care


ST. JOHN'S, Newfoundland and Labrador, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Canadian Labour Congress president Bea Bruske made the following statement today:

"Decades of cuts and privatization in the long-term care sector have had tragic consequences during this crisis.

"Early in the pandemic, long-term care homes accounted for four out of every five COVID-19 related deaths in Canada. In Ontario, the Commission into long-term care said for-profit companies should no longer be in charge of care.

"The for-profit model has clearly failed seniors and their families. We welcome Jagmeet Singh and the New Democrats' commitment to take profit out of long-term care.

"For years, long-term care workers, unions and advocates for senor's health care have demanded systemic change to a broken system.

"Canada's unions have been fighting for long-term care to be offered as a public service. This means making major changes to Canada's long-term care sector, including regulating long-term care under the Canada Health Act."

Canada's unions have been calling on governments to address the failings COVID-19 exposed in long-term care by:

Full recommendations on Long-term care can be found here.

To arrange an interview, please contact:
CLC Media Relations
[email protected]
613-355-1962



These press releases may also interest you

at 17:35
Genmab A/S today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of follicular lymphoma...

at 08:05
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody...

at 08:05
Detailed positive results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 08:05
Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...

1 jun 2024
Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type...

1 jun 2024
Taseko Mines Limited (LSE: TKO) ("Taseko" or the "Company") announced today that operations at the Company's Gibraltar Mine have been suspended. Collective bargaining with Gibraltar's union representatives has been ongoing in recent weeks, and...



News published on and distributed by: